gd2-cart01
Cell therapyexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2022 (NCT05298995)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Disialoganglioside GD2BINDING AGENT
Disialoganglioside GD2 binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05298995 | Phase 1 | May 31, 2022 | Bambino Gesù Hospital and Research Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bambino Gesù Hospital and Research Institute | Academic/Hospital | 1 | 1 | 1 | 2022 |
1 organizations
Page 1 / 1